LIVER FIBROSIS RESPONSE TO ENTECAVIR TREATMENT IN PATIENTS WITH HBV-RELATED COMPENSATED CIRRHOSIS

2018 ◽  
Vol 8 (6) ◽  
pp. 203-209
Author(s):  
Trung Doan Hieu ◽  
Chuong Tran Xuan
Keyword(s):  
Hepatitis B Virus ◽  
Liver Fibrosis ◽  
Hepatitis B ◽  
Acoustic Radiation ◽  
Term Treatment ◽  
Related Factors ◽  
Compensated Cirrhosis ◽  
Long Term Treatment ◽  
B Virus

Background: Evaluating improvement of liver fibrosis response after anti HBV therapy in our country until now is very limited, especially in patients with cirrhosis. This study aimed at assessing the respone in liver fibrosis determined by ARFI and its related factors for patients with compensated HBV-related cirrhosis undergoing entecavir therapy. Subjects and methods: 60 patients with compensated HBV-related cirrhosis were enrolled at Da Nang Hospital from 06/2016 to 06/2018. All received entecavir 0,5mg a day 2 hours after breakfast and followed in 18 months. Liver fibrosis is measured by Acoustic Radiation Forced Imaging (ARFI). Results: Entecavir treatment may result in improvement of liver fibrosis in 20% after 12 months and 26.67% after 18 months in patients with compensated hepatitis B virus-related cirrhosis. The improvement in fibrosis levels was significant after at least 12 months of treatment. Factors associated with improvement of fibrosis response in this study included AST, ALT, AFP are high, HBeAg (+), low prothrombin time at baseline, and indetectable HBV DNA after 6 months of treatment. Conclusion: Entecavir treatment may help to improve liver fibrosis in patients with hepatitis B virus-related compensated cirrhosis, but long-term treatment is needed. Key words: Entecavir, HBV cirrhosis, liver fibrosis, ARFI

The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment

2003 ◽  
Vol 38 (3) ◽  
pp. 315-321 ◽  
Author(s):  
Norio Akuta ◽  
Fumitaka Suzuki ◽  
Mariko Kobayashi ◽  
Akihito Tsubota ◽  
Yoshiyuki Suzuki ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Term Treatment ◽  
Virus Genotype ◽  
Lamivudine Resistance ◽  
Long Term Treatment ◽  
B Virus

BIOCHEMICAL, VIROLOGICAL AND THE FIBROSIS RESPONSES TO TENOFOVIR DISOPROXIL FUMARATE IN PATIENTS WITH HBV-RELATED COMPENSATED CIRRHOSIS

2016 ◽  
pp. 14-18
Author(s):  
Van Huy Tran ◽  
Phuoc Bao Quan Nguyen
Keyword(s):  
Tenofovir Disoproxil Fumarate ◽  
Acoustic Radiation ◽  
Term Treatment ◽  
Remarkable Improvement ◽  
Compensated Cirrhosis ◽  
Long Term Treatment ◽  
Tenofovir Df ◽  
Cirrhotic Patients ◽  
The Mean

Background: Preliminary studies showed anti HBV nucleoside analogues treatment might improve the histopathology and improve the survival of the cirrhotic patients. Data about efficacy of anti-HBV treatment in Vietnamese cirrhotic patients was still very limited. This study was aimed at assessing the biochemical, virological and the fibrosis responses to Tenofovir disoproxil fumarate (Tenofovir DF) in patients with HBVrelated compensated cirrhosis. Patients and methods: 48 patients of HBV-related compensated cirrhosis, diagnosed by Acoustic radiation Forced Imaging (ARFI), were enrolled. Tenofovir DF was given at dose of 300 mg per day, followed in 24 months. Results: ALT normalization and HBV DNA responses were found in 91.7% and 87.5%, respectively, of all patients. The mean of SWV was significantly improved after 24 months, from 2.16 ± 0.28 m/s down to 1.80± 0.22 m/s after 24 months of tenofovir treatment. Especially, 15 patients (31.2%) have obtained a remarkable improvement of fibrosis from F4 down to F3 or even F2. Conclusion: Tenofovir treatment in patients with HBV- related compensated cirrhosis may provide not only biochemical and virological responses but also improves in liver fibrosis, especially after long-term treatment. Key words: HBV, Tenofovir disoproxil fumarate, compensated cirrhosis, ARFI

scholarly journals Lamivudine Revisited: Long-Term Treatment of Relatively Low-Viremic Hepatitis B Patients on Higher-Dose Lamivudine

2020 ◽  
Vol 2 (11) ◽  
Keyword(s):  
Hepatitis B ◽  
The United States ◽  
Term Treatment ◽  
Oral Drugs ◽  
Long Term Treatment ◽  
B Virus ◽  
Time Periods ◽  
Tenofovir Alafenamide ◽  
Global Health Problem

Hepatitis B virus (HBV) is a significant global health problem with more than 350 million people chronically infected. Currently it is believed that HBV is responsible for 50% of hepatocellular carcinoma (HCC) worldwide [1-3]. While a cure for HBV is still needed, several oral drugs that suppress viral replication exist. In the United States, six nucleos(t)ide analogues that have been approved at different time periods include lamivudine (1998), adefovir (2002), entecavir (2005), telbivudine (2006), tenofovir disoproxil fumarate (2008) and tenofovir alafenamide (2016).

Serum ceruloplasmin can predict liver fibrosis in hepatitis B virus-infected patients

2020 ◽  
Vol 26 (27) ◽  
pp. 3948-3958
Author(s):  
Na-Ling Kang ◽  
Jie-Min Zhang ◽  
Meng-Xin Lin ◽  
Xu-Dong Chen ◽  
Zu-Xiong Huang ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Liver Fibrosis ◽  
Hepatitis B ◽  
Serum Ceruloplasmin ◽  
B Virus

Decline in serum 25-OH vitamin D levels in HIV/hepatitis B virus (HBV) co-infected patients after long term antiretroviral therapy

2013 ◽  
Vol 19 (1) ◽  
pp. 41-49 ◽  
Author(s):  
Anchalee Avihingsanon ◽  
◽  
Tanakorn Apornpong ◽  
Reshmie A Ramautarsing ◽  
Sasiwimol Ubolyam ◽  
...  
Keyword(s):  
Vitamin D ◽  
Hepatitis B Virus ◽  
Antiretroviral Therapy ◽  
Hepatitis B ◽  
Vitamin D Levels ◽  
B Virus ◽  
25 Oh Vitamin D
Sign in / Sign up

Export Citation Format

Share Document